NOVAVAX INC reported first-quarter revenue of $139.5 million, beating analyst estimates of $78.3 million. Milestone payments from licensing deals offset declining demand for COVID-19 shots. The beat sent shares up 7% in premarket trading.

Licensing Strategy Drives Revenue Beat